ホーム   >  トピックス   >   オープンアクセス記事   >  オープンアクセス 2023年   > Safety and tolerability of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: first interim report of a 2-year post-marketing surveillance(2023年10月号) [オープンアクセス]
  • ABSTRACT
  • INTRODUCTION
  • PATIENTS AND METHODS
    • 1   Study design
    • 2   Patients and treatment
    • 3   Data collection
    • 4   Outcomes and safety analysis
  • RESULTS
    • 1   Patient disposition and characteristics
    • 2   Nintedanib treatment
    • 3   Frequency and incidence of adverse drug reactions
    • 4   Frequency and incidence of adverse events
  • DISCUSSION
  • CONCLUSION
  • REFERENCES

▲このページの上へもどる